Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

4.45
Delayed Data
As of 12:18pm ET
 -0.12 / -2.63%
Today’s Change
1.45
Today|||52-Week Range
6.30
-15.56%
Year-to-Date
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
Jan 12 / Zacks.com - Paid Partner Content
Can The Uptrend Continue for Conatus (CNAT)?
Jan 11 / Zacks.com - Paid Partner Content
NuVasive at 52-Week High on Preliminary Results, MHLW Nod
Jan 12 / Zacks.com - Paid Partner Content
Align Poised On Global Expansion & Invisalign Teen Growth
Jan 11 / Zacks.com - Paid Partner Content
Walgreens Teams Up with Fedex to Boost Retail Performance
Jan 12 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close4.57
Today’s open4.62
Day’s range4.37 - 4.62
Volume163,683
Average volume (3 months)1,540,530
Market cap$119.1M
Dividend yield--
Data as of 12:18pm ET, 01/24/2017

Growth & Valuation

Earnings growth (last year)+9.72%
Earnings growth (this year)+1.28%
Earnings growth (next 5 years)+74.00%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book2.63

Competitors

 Today’s
change
Today’s
% change
--EcoGreen Internation...+0.02+10.93%
ACRXAcelRx Pharmaceutica...0.000.00%
ALBOAlbireo Pharma Inc-0.05-0.27%
ATHXAthersys Inc+0.01+0.71%
Data as of 12:18pm ET, 01/24/2017

Financials

Next reporting dateMarch 15, 2017
EPS forecast (this quarter)-$0.33
Annual revenue (last year)$0.00
Annual profit (last year)-$24.1M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Steven J. Mento
Chief Financial Officer, Secretary &
SVP-Finance
Charles J. Cashion
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs